Skip to main content
TipRanks
Go Ultimate75% OFF

ADMA Biologics (ADMA) AI Stock Analysis

3,063 Followers
ADMA

ADMA Biologics

(NASDAQ:ADMA)

Select Model
Rating:77Outperform
Price Target:$15.00â–²(10.05% Upside)
Action:reiterated
Date:11/06/26

The score is driven primarily by strong financial performance (high margins and robust operating/free cash flow) and a constructive earnings update with raised profitability guidance and ongoing share repurchases. Technicals support the trend, but near-overbought RSI adds short-term risk. Valuation is reasonable at a 16.721 P/E, while leverage and working-capital (DSO) pressure remain the key offsets.

Positive Factors
ASCENIV GrowthASCENIV is showing strong commercial traction through broader physician adoption, new patient starts, and recurring demand. Continued penetration of its targeted primary-immunodeficiency market can support durable revenue growth, while increasing patient retention may improve the predictability of future sales.
Negative Factors
BIVIGAM DeclineBIVIGAM’s sustained revenue decline shows that competition and pricing pressure remain meaningful within standard immunoglobulin. Continued weakness could offset growth from ASCENIV, constrain overall portfolio expansion, and make future revenue growth more dependent on one principal product.

ADMA Biologics (ADMA) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%40%ADMA-16.69%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$3.02B
Dividend Yield
―
Average Volume (3M)
3.19M
Price to Earnings (P/E)
17.1
Beta (1Y)
0.71
Revenue Growth
6.26%
EPS Growth
-10.51%
Country
US
Employees
644
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

ADMA Biologics Business Overview & Revenue Model

Company Description

ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune...

How the Company Makes Money

ADMA primarily makes money by selling plasma-derived therapeutic products to healthcare providers and channel partners. Its key revenue stream is product sales of immune globulin (IG) therapies and other plasma-derived biologics that are manufactured...

ADMA Biologics Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:30.06%|Next Earnings Date:Mar 25, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. ASCENIV delivered accelerating revenue growth, expanded margins, substantial earnings and cash-flow growth, and durable patient-demand indicators. The company raised minimum adjusted EBITDA and adjusted net income guidance, continued significant share repurchases, and reported constructive FDA feedback for SG-001. The main challenges were BIVIGAM's revenue decline, persistent pricing and competitive pressure in the standard IG market, moderate secondary immunodeficiency growth, and DSOs remaining above the target range.

Positive Updates

ASCENIV Revenue Growth Accelerated
Third-quarter ASCENIV revenue reached $124.7 million, increasing 31% year-over-year and 21% sequentially. Growth was driven by broader physician adoption, new patient starts, increasing end-user utilization, medical education activities, real-world evidence, and expanded sales-force presence.

Negative Updates

BIVIGAM Revenue Declined
Third-quarter BIVIGAM revenue was $15.4 million, down from $19.4 million in the second quarter and $23.8 million a year ago. Standard IG pricing and competitive pressures weighed on reported revenue.

Company Guidance

The company reiterated full year 2026 revenue guidance of at least $530 million, increased minimum adjusted EBITDA guidance to at least $275 million from $265 million previously, and increased minimum adjusted net income guidance to at least $180 million from $170 million previously; it continues to execute against a target of $200 million or more in total share repurchases during 2026. Management said ASCENIV month-to-month growth remains within the previously stated 2% to 4% growth expectation and estimated full-year growth at about 25%, maybe a little more than that, while SG-001 represents a potential $300 million to $500 million annual revenue opportunity. The DSO target remains between 90 to 105 days, Q4 R&D spend is expected to be probably close to $10 million, and management expects to provide firm clinical timelines sometime next year.

ADMA Biologics Financial Statement Overview

Summary

Strong turnaround with TTM revenue of $519.2M, high gross margin (~68.5%) and net margin (~35.1%), plus solid cash generation (TTM operating cash flow ~$140.8M; free cash flow ~$132.9M with good conversion vs. net income). Offsets are higher leverage versus last year (TTM debt ~$202.8M; debt-to-equity ~0.46) and historical volatility in growth and cash-flow consistency.

Income Statement

86Very Positive

Balance Sheet

68Positive

Cash Flow

79Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue519.15M510.17M426.45M258.21M154.08M80.94M
Gross Profit355.76M292.76M219.55M88.94M35.27M1.17M
EBITDA252.60M197.86M147.69M5.12M-39.51M-53.10M
Net Income182.41M146.93M197.67M-28.24M-65.90M-71.65M
Balance Sheet
Total Assets732.49M624.24M488.68M329.18M348.46M276.25M
Cash, Cash Equivalents and Short-Term Investments124.56M87.63M103.15M51.35M86.52M51.09M
Total Debt202.80M79.89M82.12M141.42M154.44M102.92M
Total Liabilities293.98M146.92M139.66M193.98M196.49M135.08M
Stockholders Equity438.51M477.32M349.02M135.21M151.97M141.17M
Cash Flow
Free Cash Flow132.91M27.82M110.10M3.82M-73.42M-125.88M
Operating Cash Flow140.79M50.40M118.67M8.80M-59.51M-112.37M
Investing Cash Flow-2.20M-21.89M-8.57M-4.98M-13.91M-13.51M
Financing Cash Flow-75.43M-44.02M-58.30M-38.99M108.85M121.05M

ADMA Biologics Technical Analysis

Technical Analysis SentimentPositive
Last Price13.63

Price Trends

50DMA10.73Positive
100DMA9.95Positive
200DMA10.69Positive

Market Momentum

MACD0.82Negative
RSI69.13Neutral
STOCH85.04Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADMA, the sentiment is Positive. The current price of 13.63 is above the 20-day moving average (MA) of 12.03, above the 50-day MA of 10.73, and above the 200-day MA of 10.69, indicating a bullish trend. The MACD of 0.82 indicates Negative momentum. The RSI at 69.13 is Neutral, neither overbought nor oversold. The STOCH value of 85.04 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ADMA.

ADMA Biologics Risk Analysis

ADMA Biologics disclosed 59 risk factors in its most recent earnings report. ADMA Biologics reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.Provisions in our charter documents could prevent or delay stockholders' attempts to takeover our company.Q3, 2026
2.We and certain of our directors and officers have been named as defendants in a securities class action lawsuit and in derivative actions. This lawsuit and these actions, and any similar or related proceedings that may be filed in the future, could result in substantial costs, divert management's attention and resources from our business, and may have a material adverse effect on our business, financial condition, results of operations and cash flows.Q3, 2026
3.Many of our business practices are subject to scrutiny by federal and state regulatory authorities, as well as to lawsuits brought by private citizens under federal and state laws. Failure to comply with applicable law or an adverse decision in lawsuits may result in adverse consequences to us.Q2, 2024

ADMA Biologics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ADMA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AUPHAUPH84Outperform$2.06B6.4551.92%―21.04%312.89%
RIGLRIGL79Outperform$808.18M2.5373.94%―2.18%165.65%
ADMAADMA77Outperform$3.02B17.0742.56%―6.26%-10.51%
PHARPHAR74Outperform$872.71M35.078.96%―6.67%2242.07%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
OMEROMER50Neutral$1.04B8.78-120.76%―――
BCRXBCRX49Neutral$1.93B-5.5294.36%―60.30%-3028.57%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%ADMABCRXOMERRIGLAUPHPHARDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ADMA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ADMAADMA Biologics Inc13.63-2.32-14.55%
BCRXBioCryst Pharmaceuticals7.500.578.23%
OMEROmeros Corporation13.925.7069.34%
RIGLRigel Pharmaceuticals42.921.242.98%
AUPHAurinia Pharmaceuticals15.400.201.32%
PHARPharming Group Nv12.06-4.05-25.14%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026